sni held capit market day new ceo paul hudson outlin vision
mani posit chang outlin relat strategi focu platform howev
vision need implement deliv remain market perform sni
pend visibl success updat model attach reflect increas estim
mainli relat guidanc higher margin
although ambiti sni low/mid-thirti busi oper incom boi margin
would place compani peer averag margin expans expect
driven top-line growth guidanc provid save
de-priorit declin segment cv/diabet smart spend
reduc travel consult fee improv manufactur effici
prior guidanc spend reiter note
establish product gener less sale divest
tandem workforc reduc cut alreadi made free cash
flow expect increas busi matrix also
reorgan intent remov bureaucraci fuel innov
core global busi unit specialti immunolog disease/hematolog
vaccin
ep estim increas
newli establish ep estim
impli ep growth consist industri
averag higher last-publish estim sni higher ep estim
mainli driven new margin guidanc sale increas
year begin sni target price increas
previous given higher ep estim
consum healthcar silo eye toward improv stand-alone sale
consid move spin-off effort earn over-the-counter approv ciali
tamiflu respect could add divis top-line
push compound-annual-growth-rate high singl digit portfolio also cull reduc
number sku foray e-commerc target market may
improv busi
praluent right return regeneron kevzara right retain
 sni captur ou sni diabet cv research discontinu
includ halt develop efpeglenatid cv sni state scienc isnt
enough cardiologist arent interest new drug generic market
onduo digit collabor verili consum diabet also scale back
continu growth establish product sale lantu plavix emerg market
notabl china still expect across therapeut area new drug launch
plan china
pleas see page report import disclosur
mani posit chang underway sni relat strategi focu platform
earn visibl improv consider given new margin target pipelin
product appear improv dupix expect need achiev despit
emerg competit hemophilia competit threat bioverativ asset must
manag execut new corpor strategi deliv remain
market perform sni pend visibl success
dupix file pedi ad
china approv adult ad
fitusiran piii data hemophilia
lantu eros greater expect
sanofi sa formerli sanofi-aventi global diversifi health care compani base
franc compani focus field health care five growth platform diabet
solut human vaccin innov drug consum health care emerg market
compani portfolio prescript drug vaccin gener consum health
decemb sni own regeneron begin year sni
sold share may elect sell end lock-up expir
manag indic sale remain share would pursu
clearli superior altern capit alloc
synthorx lead candid acquir sni
recombin engin block bind receptor associ
treg expans preserv gamma receptor affin promot teff
nk cell expans boost half-lif sni head expert biolog
believ molecul best-in-class despit behind develop rel
roch variant nektar pegyl roch mutat prevent
receptor bind potenti increas immunogen risk nektar
indiscrimin pegyl exhibit prefer receptor subtyp clinic poc
data view sni yet releas develop
larg base combin inhibitor libtayo
isatuximab earlier stage pipelin candid preferenti
receptor activ increas treg may use autoimmun disord
dupix vaccin re-focus pipelin includ key asset fitusiran
venglustat nirsevimab sni focu go forward although
strict guidanc sni aspir gener new launch intern
last drug launch came within compani acquisit nanobodi
platform compani ablynx improv sni intern capabl reduc relianc
partner regeneron antibodi develop sni plan host meet
like
dupix manag guid peak sale exclud copd potenti
new clinic stage indic assum success achiev
number way atop dermat largest opportun follow asthma
interim analysi copd studi mid growth expect come
label expans dermatolog respiratori indic ex-u approv
market expans especi among younger patient popul sni believ
latter push enabl uniqu safeti profil elig patient popul under-
penetr dupix candid nave biolog ex-u launch
dupix on-going china approv expect end us rebat
yet consid improv formulari posit term competit
landscap jak inhibitor pfe abrocitinib larg dismiss dermatolog
given unfavor safeti profil sni provid long-list safeti concern
abrocitinib superior dupix achiev note
distinguish dupix sni believ unlik get approv azn
anti-tslp mab tezepelumab could pose threat duplix asthma strong phase iib
data hold phase
vaccin high capit alloc long lead time justifi back end sustain
vaccin franchis three core franchis pph booster influenza mening plu
rsv make bulk revenu mid-to-high singl digit sale growth expect
pph booster growth come us introduct vax
increas booster manufactur capac meet demand influenza growth come
fluzon high-dos improv efficaci age ph pediatr patient
start flublok recombin vaccin take advantag
quadrival coverag fda also allow promot relat associ
influenza vaccin reduc cardio-respiratori diseas mening growth
come new menquadfi improv efficaci profil pdufa ultim
develop pentaval vaccin current seek optimum men candid
add menquadfi rsv growth come primarili develop nirsevamib
infant first year life see addit intranas live attenu rsv
vaccin use infant first season exposur develop although
core focu sni also work pneumococc vaccin enter ph ii rival
specif valenc coverag potenti differenti state
appear us vaccin valenc might work
manufactur capac built readi commerci suppli registr
expect year sni also explor mrna-bas vaccin adjuv
clinic addit candid follow sni believ gsk blaze
path adjuv sni catch collabor work hiv vaccin
target specif region africa continu appar effort rekindl
work diff copd vaccin
fitusiran antithrombin rnai hemophilia plan submiss
product includ list priorit program sni believ
hemlibra rhhbi success come almost entir conveni allow sc
dose fitusiran exhibit better efficaci administ
conveni schedul achiev better efficaci fitusiran annual
bleed rate ph ii ole interim hemlibra would dose weekli abr
ph patient rather receiv abr
abr inject fitusiran efficaci must still confirm sni believ
differ abr would clinic meaning phase atla program
enrol sni also note fitusiran requir cold chain suppli
come antidot prevent thrombosi highlight death report
hemlibra without go far suggest drug-rel rel fitusiran
safeti beyond one death atrial clot seizur case elev lft profil
look accept lentiviral-bas gene therapi also explor
oral serd hr breast cancer plan submiss clinic data
expect reduc cardiotox diarrhea risk may differenti
competit oral serd roch azn potenti enabl use earli stage
breast cancer combin studi inhibitor pfe ibranc plan
monotherapi initi focu sni believ inhibitor realli
differ despit fact lli verzenio nv kisqali shown os ibranc
long-act rfviiifc-vwf-xten hemophilia plan submiss
factor replac therapi normal clot function differenti
come conveni half-lif day market segment patient
activ lifestyl need normal bleed risk especi joint expect
gravit therapi
venglustat gsc inhibitor lsd pkd pd plan submiss gene
therapi come lsd sni believ still place oral therapi
polycyst kidney diseas pkd parkinson diseas pd repres sizabl patient
popul upsid venglustat expect pkd program current preclin
pd program ph ii enrol pd patient known mutat gba similar
gaucher patient pd trial repres one first attempt precis
medicin pd fda request ph program includ patient without
biomark cogniz field shift toward gene therapi sni plan build in-hous
manufactur capabl part re-purpos vaccin expertis aav lentivir
base vector explor payload target undisclos earli
stage bd area possibl heighten focu ftc scrutini factor
nirsevimab anti-rsv mab plan submiss rsv lead caus infant
hospit larg unmet need nirsevimab provid passiv immun infant
month old last entir winter season tradit rsv vaccin safe
popul price like vaccine-lik although flu vaccine-lik order extend
reach drug howev benchmark cost hospit work
favor nirsevimab pharmacoeconom
btk inhibitor ms plan submiss compound may
brain penetr btk inhibitor despit rise cell-deplet
therapi ocrevu rhhbi ofatumumab nv sni think
role oral therapi may replac aubagio post loe direct
effect microglia could potenti differenti addit faster cell rebound
shorter half-lif molecul could improv infect risk four phase trial readi
launch poc data read sni note ofatumumab studi brain volum
impact similar aubagio
sarclisa isatuximab mab mm launch expect mm
although highlight key pipelin product view first-in-
class potenti best-in-class honor may go jnj darzalex sarclisa may
import drug sni focu expand class sc
formul elut devic also investig well combin
regeneron bispecif sni own option latter
compani data cowen compani estim
net sale total gross non-op inc report tax rateshar profit assoc busi net incomesharesmm chg slsmm revmm revmm revmm mmmmepschg sale exclud revenu revenu predominantli royalti incomeoper incsg ar cowen
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
blood disord blood disord lc blood disord blood disord emerg countri blood disord emerg countri lc blood disord row blood disord row lc total blood oncolog hemophilia gbu sanofi genzym gbu sanofi genzym gbu sanofi genzym emerg countri fx gbu sanofi genzym row sanofi genzyme/specialti lantu lantu lantu lantu emerg countri lantu emerg countri lantu row lantu row apidra apidra apidra apidra emerg countri apidra emerg countri apidra row apidra row amaryl amaryl amaryl amaryl emerg countri amaryl emerg countri amaryl row amaryl row cowen
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
 row primari emerg market diabet emerg market sanofi emerg total total total emerg countri total row healthcar consum healthcar consum healthcar consum healthcar consum healthcar emerg countri consum healthcar emerg countri consum healthcar row consum healthcar row bi consum healthcar polio/pertussis/hib polio/pertussis/hib polio/pertussis/hib polio/p/hib emerg countri polio/p/hib emerg countri polio/pertussis/hib row polio/pertussis/hib row total cowen
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
sclerosi aubagio share via settlement gener launch aubagio aubagio eu exclus expir aubagio emerg countri aubagio emerg countri aubagio row aubagio row aubagio oral ms monotx/adjunct tx ci pedi file lemtrada decemb label warn ad januari lemtrada rxn assoc infus auto-immun hepat haemophagocyt lymphohistiocytosi lemtrada warn ad april lemtrada emerg countri market lemtrada emerg countri lemtrada row lemtrada row lemtrada mab rr multipl sclerosi pedi file inhibitor multipl sclerosi file total multipl sclerosi total multipl sclerosi total multipl sclerosi emerg countri total multipl sclerosi row total multipl sclerosi sale doubl diseas cerezym suppli establish allston plant ad two bioreactor cerezym cerezym build global suppli cerezym emerg countri cerezym emerg countri cerezym row cerezym row enzym replac therapi type gaucher diseas cerdelga studi complet eu initi cerdelga cerdelga cerdelga emerg countri cerdelga emerg countri cerdelga row cerdelga row synthetas inh gaucher diseas adult cowen
compani data cowen compani estim
myozyme/lumizym myozyme/lumizym myozyme/lumizym myozyme/lumizym emerg countri myozyme/lumizym emerg countri myozyme/lumizym row myozyme/lumizym row diseas infantile-onset myozym late-onset lumizym fabrazym suppli establish framingham plant approv amicu galafold approv august fabrazym fabrazym build global suppli oral galafold amicu threat post approv fabrazym emerg countri fabrazym emerg countri fabrazym row fabrazym row diseas aldurazym aldurazym aldurazym aldurazym emerg countri aldurazym emerg countri aldurazym row aldurazym row diseas continuedavalglucosidas pomp diseas phase file gc inhib gaucher gaucher-rel pd adpkd file defici acid sphingomyelinas defici file gene therapi stargardt diseas phase alport syndrom phase ii nda diseas product diseas product diseas product diseas product emerg countri diseas product emerg countri diseas product row diseas product row diseas product cowen
compani data cowen compani estim
total diseas total diseas total diseas emerg countri total diseas row diseas taxoter pat expir hospira approv taxoter taxoter patent expir countri taxoter emerg countri taxoter emerg countri taxoter row japan prca patent expir canada australia new zealand japan taxoter row jevtana expir jevtana jevtana jevtana emerg countri jevtana emerg countri jevtana row jevtana row taxoter refactori prostat cancer phase metastat pc phase ii testicular cancer breast cancer ovarian liposarcoma eloxatin dominant eloxatin eloxatin form gener market eloxatin emerg countri eloxatin emerg countri eloxatin row growth canada australia new zealand japan eloxatin row thymoglobulin thymoglobulin thymoglobulin thymoglobulin emerg countri thymoglobulin emerg countri thymoglobulin row thymoglobulin row cowen
compani data cowen compani estim
mozobil mozobil mozobil mozobil emerg countri mozobil emerg countri mozobil row mozobil row zaltrap approv zaltrap zaltrap approv zaltrap emerg countri zaltrap emerg countri zaltrap row zaltrap row vegf-trap piii line mprca line nsclc line mcrc via oncolog oncolog oncolog oncolog emerg countri oncolog emerg countri oncolog row oncolog row oncolog inhibitor advanc cscc skin cancer approv us/eu piii adj cscc nsclc cervic file sni record ou nake mab relapsed/refractori multipl myeloma file file file aml pedi mm te file nsclc file total oncolog total oncolog total oncolog emerg countri total oncolog row oncolog dupix dermat apprv asthma adolesc ad csrwnp dupix dupix dermat apprv asthma dupix emerg countri dupix emerg countri dupix row dupix row mab sni guidanc peak cowen
compani data cowen compani estim
kevzara kevzara kevzara kevzara emerg countri kevzara emerg countri kevzara row kevzara row mab ra juvenil arthriti file uveiti system scleroderma file total immunolog total immunolog total immunolog emerg countri total immunolog row eloct eloct eloct eloct emerg countri eloct emerg countri eloct row eloct row factor fc fusion protein prevention/control hemophilia bleed alprolix alprolix alprolix alprolix emerg countri alprolix emerg countri alprolix row alprolix row ix fc fusion protein prophylaxis/treat hemophilia bleed cablivi bival anti-vwf nanobodi acquir ttp us approv eu cablivi cablivi cablivi emerg countri cablivi emerg countri cablivi row cabilivi row acquir cash close mab cold agglutinin diseas phase data file target anti-thrombin hemophilia type with/out inhibitor file blood disord blood disord blood disord blood disord emerg countri blood disord emerg countri blood disord row blood disord row blood disord revenu cowen
compani data cowen compani estim
blood disord blood disord lc blood disord blood disord emerg countri blood disord emerg countri lc blood disord row blood disord row lc total blood acquir cash close oncolog hemophilia gbu sanofi genzym gbu sanofi genzym gbu sanofi genzym emerg countri fx -line elimin given record gbu gener medicin em gbu sanofi genzym row sanofi genzyme/specialti double-digit sale compound-annual-growth-rate lantu share solostar share pat exp month pedi biosimilar launch lantu lantu expir biosimilar launch mid lantu emerg countri lantu emerg countri lantu row launch japan canada australia new zealand japan lantu row insulin apidra share rapid act insulin market launch solostar formul unsuccess apidra apidra apidra emerg countri apidra emerg countri apidra row australia new zealand japan apidra row act insulin insulin market amaryl sulphonylurea diabet amaryl amaryl amaryl emerg countri amaryl emerg countri amaryl row metformin launch canada australia new zealand japan amaryl row cowen
compani data cowen compani estim
insuman insuman insuman insuman emerg countri insuman emerg countri insuman row insuman row rapid insulin-mix germani bgm bgm bgm bgm emerg countri bgm emerg countri bgm row bgm row glucos monitor system lyxumia/adlyxin approv juli brand name adlyxin lyxumia/adlyxin lyxumia lyxumia emerg countri lyxumia emerg countri lyxumia row lyxumia row agonist differenti vs unclear type diabet toujeo fx toujeo solostar share toujeo toujeo toujeo emerg countri toujeo emerg countri toujeo row australia new zealand japan toujeo row concentr lantu type insulin lispro type diabet approv ratio lixisenatide/lantu combo approv act insulin type i/ii diabet phase file eu cowen
compani data cowen compani estim
diabet diabet diabet diabet emerg countri diabet emerg countri diabet row diabet row diabet total diabet total diabet total diabet emerg countri total diabet row diabet multaq multaq multaq reimburs multaq emerg countri multaq emerg countri multaq row multaq row australia new zealand japanmultaq anti-arrhythm atrial fibril praluent right return regeneron earli praluent lc praluent praluent emerg countri praluent emerg countri praluent row praluent row mab hypercholesterolemia ou right bi-specif mab system scleroderma file total cardiovascular total cardiovascular total cardiovascular emerg countri total cardiovascular row cardiovascular gbu diabet cardiovascular gbu diabet cardiovascular gbu diabet cardiovascular emerg countri fx -line elimin given record gbu gener medicin em gbu diabet cardiovascular row cardiovascular total growth begin sale line monoclon antibodi atop dermat asthma copd phase ii file respiratori syncyti viru monoclon antibodi file cowen
compani data cowen compani estim
rx product plavix domin plavix plavix adopt non ab-rat gener eu plavix emerg countri plavix emerg countri full econom china plavix row plavix row launch japan canada australia new zealand japanplavix lovenox pressur lovenox lovenox lovenox emerg countri lovenox emerg countri lovenox row lovenox row australia new zealand japanlovenox renagel/renvela powder tablet avail renagel/renvela renagel/renvela expir gener launch renagel/renvela emerg countri renagel/renvela emerg countri renagel/renvela row renagel/renvela row serum phosphoru pt chronic kidney diseas ckd aprovel aprovel aprovel franc germani patent expir countri aprovel emerg countri aprovel emerg countri aprovel row aprovel row patent expir canada australia new zealand japanaprovel allegra pressur allegra allegra allegra emerg countri allegra emerg countri allegra row australia new zealand japan allegra row cowen
compani data cowen compani estim
rx product continu ambien/cr ambien/cr ambien/cr ambien/cr emerg countri ambien/cr emerg countri ambien/cr row japan regulatori exclus exp canada australia new zealand japan ambien/cr row synvisc synvisc synvisc synvisc emerg countri synvisc emerg countri synvisc row synvisc row pain osteoarthr oa knee depakin epilepsi mood stabil depakin emerg countri depakin emerg countri depakin row australia new zealand japan depakin row tritac inhibitor gener launch tritac emerg countri tritac emerg countri tritac row tritac row australia new zealand japantritac lasix lasix lasix lasix emerg countri lasix emerg countri lasix row lasix row lasix targocid targocid emerg countri targocid emerg countri targocid row targocid row cowen
compani data cowen compani estim
rx product continu orudi orudi emerg countri orudi emerg countri orudi row orudi row cordaron cordaron emerg countri cordaron emerg countri cordaron row cordaron row xatral gener launch xatral xatral launch major xatral emerg countri xatral emerg countri xatral row australia new zealand japan xatral row gener gener gener close end gener emerg countri gener emerg countri gener row gener row rx drug rx drug rx drug rx drug emerg countri rx drug emerg countri rx drug row rx drug row rx drug total establish rx product total establish rx product total establish rx product emerg countri total establish rx product row establish rx cowen
compani data cowen compani estim
 row primari low single-digit sale compound-annual-growth-rate emerg market diabet market sale gbu diabet cardiovasculartot emerg market sanofi market sale gbu sanofi genzymechina emerg emerg countri total record gbu gener em sale row care consum care consum care consum care consum care emerg countri consum care emerg countri consum care row consum care row bi consum care merial anim bi close polio/pertussis/hib polio/pertussis/hib polio/pertussis/hib polio/p/hib emerg countri polio/p/hib emerg countri polio/pertussis/hib row australia new zealand japan polio/pertussis/hib row total vaccin develop economi contract award cowen
compani data cowen compani estim
 continu adult booster vaccin adult booster vaccin adult booster vaccin adult booster emerg countri adult booster emerg countri adult booster vaccin row australia new zealand japan adult booster vaccin row booster vaccin meningitis/pneumonia vaccin recommend usag month age meningitis/pneumonia vaccin meningitis/pneumonia vaccin meningitis/p emerg countri meningitis/p emerg countri meningitis/pneumonia vaccin row australia new zealand japan meningitis/pneumonia vaccin row vaccin men market pediatr men approv influenza vaccin influenza vaccin influenza vaccin influenza emerg countri influenza emerg countri influenza vaccin row australia new zealand japan influenza vaccin row vaccin travel vaccin travel vaccin travel vaccin travel vaccin emerg countri travel vaccin emerg countri travel vaccin row australia new zealand japan travel vaccin row vaccin dengvaxia approv endem area w/document prior infect dengvaxia dengvaxia use endem area dengvaxia emerg countri mexico philippin brazil el salvador costa rica dengvaxia emerg countri dengvaxia row dengvaxia row fever neg impact unexpos popul derail salesy/i changenmnmnmnmnmnmnmnm cowen
compani data cowen compani estim
vaccin revenu reord revenu vaccin vaccin vaccin emerg countri vaccin emerg countri vaccin row australia new zealand japan vaccin row vaccin gen acyw rabi vrvg tuberculosi adacel hiv y/i gbu vaccin gbu vaccin gbu vaccin emerg countri gbu vaccin row vaccin total mid-to-high singl digit growth cery/i total group total group total group emerg countri total group row group total guidanc sale mid-singl digit cer guidanc reiteratedy/i cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl lantu rare
diseas portfolio success pipelin product success deal patent
litig patent expir pressur biosimilar risk
